The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwMyeloma 2022 | Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics
Following a fantastic first day at the Myeloma 2022 meeting, the experts come together to discuss their highlights. The speakers place emphasis on updates shared on peripheral blood measurable residual disease (MRD) in myeloma and the prognostic capabilities of such technology. The discussion goes on to review mass spectrometry versus whole-genome sequencing in MRD, antibody treatment for amyloidosis, hot updates in single-cell technologies, and finally the emerging importance of metabolomics. Keith Stewart, MB, ChB, of Princess Margaret Cancer Centre, Toronto, Canada, chairs this session with Gareth Morgan, MD, PhD, FRCP, FRCPath, of NYU Langone Medical Center, New York, NY, and Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone Medical Center, New York, NY. This discussion took place at The International Workshop on Myeloma 2022, held in Scottsdale, AZ.
